BPC-157 Prescription in the United States: What Changed and What Did Not

No. There is no FDA-approved BPC-157 product in the United States, for any indication and for any route of administration. That single fact is the starting point for every question about a BPC-157 prescription, because it means no clinician can write for a licensed, commercially manufactured BPC-157 medicine: none exists.

What exists instead is a narrow and conditional regulatory pathway: preparation by a pharmacy or a physician under section 503A of the Federal Food, Drug, and Cosmetic Act, the provision that exempts traditional compounding from certain approval, labeling and manufacturing requirements. Compounding is not approval. A compounded preparation has not been reviewed by the FDA for safety, effectiveness or manufacturing quality, and that caveat applies in full to BPC-157.

The scientific picture explains why the regulatory picture is cautious. Published work on BPC-157 is overwhelmingly preclinical. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine concluded that, despite a substantial body of animal evidence and high public interest, well-designed human trials are still needed to assess safety, efficacy and clinical utility in musculoskeletal medicine. A 2025 literature and patent review in Pharmaceuticals reached a comparable conclusion about the state of the evidence and about open questions on toxicity.

This article deliberately stays on the regulatory question. If you are looking for the biology, the preclinical findings and the open safety questions, those belong to the general BPC-157 guide and to our overview of peptide safety. Here we cover one thing only: what the current United States prescription and pharmacy preparation route actually is, and what it requires.

Educational purposes only. Nothing below is medical advice, a recommendation to use BPC-157, or a suggestion that a prescription is appropriate for anyone. Decisions of this kind belong to a licensed healthcare professional who knows the individual patient.

On October 28, 2026, the Department of Health and Human Services issued a document titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. A notice announcing it was published in the Federal Register on October 30, 2026 (document 2026-22192), and HHS opened docket HHS-OASH-2026-0496 for public comment, with comments due by November 13, 2026.

The policy describes the circumstances in which HHS does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds a drug product using any of six peptide bulk drug substances listed in the policy's Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. It is framed as an interim measure while the FDA develops, through rulemaking, the list of bulk drug substances that may be used in compounding under section 503A.

HHS gives two stated goals. The first is to expand patient access to these peptide preparations through licensed channels. The second is to discourage the continued widespread use of research-use-only peptide material, including material from foreign manufacturers, which HHS describes as posing a safety risk to United States patients. In other words, the policy's logic is substitution: move demand out of an unregulated supply chain and into one with a prescription, a licensed pharmacy and documentation.

Two limits stated in the documents matter more than the headline. First, the policy does not create a safe harbor: it is a statement of current enforcement intent, it does not bind HHS or the public, and it establishes no rights. Second, enforcement discretion is available only where all of the conditions in the policy are met. A preparation that misses one condition simply falls outside the policy, and the ordinary legal analysis of an unapproved new drug applies again.

It is also worth being precise about what kind of document this is. The Federal Register notice presents the policy as a draft open for comment, published October 30, 2026, with a two week comment window. Readers in the United States should assume the text can change.

The policy does not cover "BPC-157" as a loose label. Appendix B of the policy, published as a separate document on hhs.gov, fixes the identity of each substance and the routes of administration that fall within scope. For BPC-157, the substance named is BPC-157 acetate.

Appendix B specifies the amino acid sequence, the chemical structure, the molecular formula and the molecular weight of the substance, and lists the dosage forms within scope: subcutaneous, intramuscular, oral and topical. A preparation whose route is not on that list, or whose material does not match the stated identity, is outside the policy even if everything else about it looks compliant.

Appendix B also sets out why each substance is described the way it is. It cites updated characterization and utilization information and the recommendations of the Pharmacy Compounding Advisory Committee, while acknowledging that the FDA's Center for Drug Evaluation and Research had recommended against listing these substances. That acknowledgment sits inside the policy itself, and it is one of the clearest signals that the document is a decision about enforcement priorities rather than a scientific endorsement.

For a patient or a clinician, the practical reading of Appendix B is narrow. The identity of the active ingredient has to be documented and has to match. The route has to be one of the four listed. Anything presented as a different salt form, a different route, or an unspecified "peptide blend" is not what the policy describes.

HHS frames the policy around ten conditions that must all be satisfied together. They go beyond the baseline requirements of section 503A, and several of them are unusual in compounding practice. In substance, they cover the following.

• Listed substance. The bulk drug substance is one of the six named in Appendix A.
• Fixed identity and route. The substance matches the identity described in Appendix B (sequence, structure, molecular formula, molecular weight) and the preparation stays within the routes of administration listed there.
• A valid prescription for an identified individual patient. The preparation is compounded for a specific named patient, not produced in anticipation of demand or offered as a stock item.
• A single active pharmaceutical ingredient. The product contains one active ingredient from the list and nothing else active. HHS explains that a single-ingredient product makes it possible to attribute an adverse event or an outcome to a specific substance.
• Qualified sourcing. The original manufacturer of the ingredient is registered with the FDA, complies with current good manufacturing practice requirements, and its manufacturing location is identified on the certificate of analysis.
• A compliant certificate of analysis. The ingredient is accompanied by a valid certificate of analysis with appropriate testing, consistent with the identity described in Appendix B.
• Reporting. The compounder reports the products it compounds, serious adverse events and product quality problems, through the FDA MedWatch program.
• Specific labeling. The label bears the statement "This is a compounded drug product. Not for resale."
• Oral bioavailability documentation. For an oral preparation, the compounder maintains documentation that the specific formulation provided to the patient achieves adequate oral bioavailability in humans.
• Device limitation and residual compliance. The only delivery device contemplated is an FDA 510(k)-cleared syringe, and all other applicable requirements continue to apply.

Read together, these conditions describe a far narrower activity than the phrase "compounded peptide" suggests in general conversation. They assume a named patient, a documented supply chain, a single ingredient, a specific label and an active reporting obligation.

For readers outside the compounding world, the useful consequence is that most of what circulates as BPC-157 cannot satisfy this list, because the failure happens at the first step: the material itself was never made by an FDA-registered, CGMP-compliant manufacturer, and has no certificate of analysis identifying where it was made. Our article on the legal status of peptides covers that broader distinction in more detail.

The sourcing conditions are the operative part of the policy, and they are strict by the standards of peptide compounding. The ingredient's original manufacturer must be registered with the FDA, must comply with current good manufacturing practice requirements, and its manufacturing location must be identified on the certificate of analysis. That last requirement is what makes a repackaged or relabeled powder of unclear origin unusable under the policy.

The certificate of analysis must be valid and must come with appropriate testing. In practice, a certificate for an injectable peptide active ingredient is expected to document identity, purity, potency and contaminants, and the identity reported has to correspond to the Appendix B entry for BPC-157 acetate rather than to a generic "BPC-157" description. A certificate that names a distributor instead of the manufacturing site, or that omits the testing, does not satisfy the condition.

This has a direct consequence that HHS states as an objective rather than an afterthought. Material sold as research use only is not covered by the policy, and HHS says that discouraging its continued widespread use is part of the point of the exercise. Research-use-only vials are not supplied as pharmaceutical-grade active ingredient for human administration, generally do not come from an FDA-registered, CGMP-compliant drug manufacturer, and therefore cannot be brought inside the policy by a pharmacy after the fact.

There is also a recordkeeping dimension that patients rarely see but can ask about. Because enforcement discretion depends on conditions being met, the documentation is the evidence that they were met: the certificate of analysis, the identity match, the manufacturer's registration, the prescription for the named patient, the reporting. A pharmacy that works within this policy should be able to describe that paper trail without hesitation.

None of this makes a compounded preparation equivalent to an approved medicine. It makes the supply chain traceable. Traceability and approval are different things, and the policy itself is careful not to conflate them.

Two of the conditions are visible to the patient, which makes them useful checks. The first is the label. A preparation compounded under the policy must bear the statement "This is a compounded drug product. Not for resale." The first sentence tells the patient what the product is, namely a compounded preparation and not an approved drug. The second closes off redistribution: a preparation made for one identified patient is not stock for anyone else.

The second visible duty is reporting. The policy requires the compounder to report the products it compounds, as well as serious adverse events and product quality problems, through the FDA's MedWatch program. This is a meaningful departure from how unregulated peptide use works today, where nothing is reported and no signal can accumulate. It is also what gives the single-ingredient condition its purpose: if a serious adverse event is reported for a product containing one active ingredient, the event can be attributed to that ingredient.

Reporting is not only a compounder obligation in practice. Patients and clinicians can submit reports to MedWatch themselves, and for an unapproved substance with no controlled human efficacy data, voluntary reporting is one of the few ways safety information is generated at all.

The combination of the label and the reporting duty also tells you how HHS expects this to be monitored. The department has said it may revise or withdraw the policy, in whole or in part, if a safety signal or a product quality problem arises with a covered preparation. The reports are the input to that decision, so the reporting condition is not administrative paperwork: it is the feedback loop on which the policy's continued existence depends.

If a product described as compounded BPC-157 carries no such labeling, or if nobody in the chain can say where adverse events would be reported, that is a signal in itself.

The policy addresses the delivery device explicitly, and the limit is narrow. The only device contemplated for co-packaging with, or containing, a covered compounded preparation is a syringe cleared by the FDA under section 510(k). HHS's stated rationale is that more complex drug delivery devices introduce additional patient risk.

On a plain reading of that text, presentations built around a more complex device fall outside the policy. That includes pens, prefilled pen presentations, cartridges and autoinjectors. The distinction is about the device, not about the peptide: the same substance, by the same route, presented in a pen rather than with a cleared syringe, is simply not what the policy describes. This is a point where marketing language and regulatory language diverge sharply, and it is worth checking directly rather than inferring.

The oral route is handled differently. BPC-157 acetate is within scope for oral dosage forms, but the policy attaches a condition specific to that route: the compounder is expected to maintain documentation confirming that the specific formulation provided to the patient achieves adequate oral bioavailability in humans. The condition is formulation-specific, not substance-specific, so documentation for one oral formulation does not transfer to another.

That condition is demanding for a reason. Peptides are generally susceptible to enzymatic degradation in the gastrointestinal tract, and human bioavailability data for a given oral peptide formulation is exactly the kind of evidence that is scarce for BPC-157. Published reviews describe a literature dominated by animal models rather than human pharmacokinetic work. A compounder who cannot produce that documentation has not met the condition, however straightforward the capsule or liquid may look.

For a reader, the device and oral conditions are the two easiest to verify, each with a single question: which device is supplied, and what human bioavailability documentation exists for this specific oral formulation.

This is the part most easily lost in summaries. The October 2026 policy is not an FDA approval of BPC-157, and it is not an addition of BPC-157 to the 503A bulk drug substances list. Those are two separate things, and the policy is neither.

Enforcement discretion means that an agency states how it currently intends to use its enforcement resources. HHS says it does not intend to take action against covered compounders who meet all the conditions. The documents state that the policy does not bind the agency or the public and establishes no rights, and legal commentators have noted that it does not create a safe harbor. The underlying status of the substance is unchanged: BPC-157 remains an unapproved drug substance.

The policy is also explicitly interim. It exists while the FDA works through rulemaking on the list of bulk drug substances that may be used in 503A compounding, and HHS has said it may revise or withdraw the policy, in whole or in part, including if a safety signal or a product quality issue arises with a preparation it covers. Anyone planning around it should treat it as a document that can change, not as a settled rule. The Federal Register notice presents it as a draft, with comments due November 13, 2026.

Finally, the policy contains a candid internal tension that readers should know about. Appendix B acknowledges that the FDA's Center for Drug Evaluation and Research recommended against listing these substances. HHS proceeded with enforcement discretion anyway, on access and supply chain grounds. Many clinicians read that disagreement as a reason for caution rather than as reassurance, and the absence of controlled human efficacy evidence for BPC-157 has not changed because an enforcement policy was published.

Disclaimer: this section describes a regulatory position, not a safety conclusion. A pathway existing on paper says nothing about whether a given substance is appropriate for a given person. That judgment belongs to a licensed healthcare professional.

The exclusions matter as much as the inclusions, and several of them are routinely misread.

• 503B outsourcing facilities are not covered. The policy addresses compounding under section 503A by state-licensed pharmacies, federal facilities and licensed physicians. It does not extend to outsourcing facilities compounding under section 503B, which operate under a different statutory regime.
• Research-use-only material is not covered. Vials sold for laboratory research sit outside the policy entirely, and HHS has said that discouraging their continued widespread use is one of its goals. A research-use-only label is not a technicality that a prescription cures.
• Multi-ingredient preparations are not covered. The single active ingredient condition excludes combination preparations, including the familiar pairings of BPC-157 with other peptides. A blend is outside the policy by definition.
• Presentations in more complex devices are not covered. As described above, a 510(k)-cleared syringe is the only device contemplated.
• Nothing outside the United States is affected. This is a United States federal enforcement policy. It has no effect on the legal status of BPC-157 in the European Union, the United Kingdom, Canada, Australia or anywhere else, and it does not create an import route for individuals.

Two further caveats sit outside the federal layer. State law and state board of pharmacy requirements continue to apply to a state-licensed pharmacy, and they can be more restrictive than a federal enforcement policy. And a federal enforcement policy says nothing about anti-doping rules: athletes subject to testing remain governed by their sport's prohibited list regardless of how a preparation was obtained.

If your question is the broader one, namely how peptides are regulated across jurisdictions and what categories such as research use only actually mean, the legal status overview is the better starting point, and the BPC-157 guide covers what the research literature does and does not show.

If you are discussing BPC-157 with a licensed clinician in the United States, the policy gives you a short list of concrete, answerable questions. None of them require specialist knowledge, and vague answers are themselves informative.

Questions for the clinician:

• Given that BPC-157 has no FDA approval and no controlled human efficacy evidence for my situation, what is the clinical reasoning for considering it rather than an approved option?
• What is known and not known about its safety profile in humans, and what would you monitor?
• How might it interact with my other medicines and conditions, and what would make you stop?
• Is the preparation being considered for one of the four routes within the policy's scope, and is it a single active ingredient?
• Where would a serious adverse event or a product quality problem be reported, and who would file it?
• If I am subject to anti-doping testing or an employer testing program, what are the consequences?

Questions for the pharmacy:

• Are you compounding this under section 503A, and are you compounding it within the HHS enforcement discretion policy dated October 28, 2026?
• Who is the original manufacturer of the active ingredient, is it registered with the FDA, and does the certificate of analysis identify the manufacturing location?
• May I see the certificate of analysis, and does the identity reported match the Appendix B entry for BPC-157 acetate?
• Does the preparation contain a single active ingredient, with no additional peptide added?
• Will the label carry the statement "This is a compounded drug product. Not for resale."?
• Which delivery device is supplied, and is it a 510(k)-cleared syringe?
• For an oral form, what documentation do you hold that this specific formulation achieves adequate oral bioavailability in humans?
• How do you report serious adverse events and product quality problems to MedWatch?

A pharmacy working inside the policy will have ready answers, because the conditions are precisely what it has to document. Hesitation on sourcing, on the certificate of analysis or on the device is a meaningful signal.

Medical disclaimer: this article is for educational purposes only and is not medical advice, a diagnosis, or an encouragement to use BPC-157. BPC-157 is not approved by the FDA for human use, the human evidence base is limited, and legal status differs by jurisdiction. Consult a qualified healthcare professional before making any decision about your health, and do not treat this page as a substitute for that consultation.